Payment overview · 2025
General Payments
$355.42
18 reported records · 10 companies
Healthcare provider profile · identity verified
Howard M Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1871541029
Verified facts
What the public records show
CMS Open Payments records show Howard M Brown, MD received $355.42 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.09 | 22.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.77 | 20.5% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.59 | 11.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.30 | 10.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.71 | 9.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.42 | 6.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.16 | 6.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.34 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.15 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.89 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.42 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $33.71 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| BYETTA Normalized: byetta |
Drug | AstraZeneca Pharmaceuticals LP | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 302 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 69 |
| Lisinopril | Lisinopril | 222 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 43 |
| Losartan Potassium | Losartan Potassium | 125 | 35 |
| Alendronate Sodium | Alendronate Sodium | 121 | 37 |
| Omeprazole | Omeprazole | 107 | 33 |
| Montelukast Sodium | Montelukast Sodium | 103 | 31 |
| Ezetimibe | Ezetimibe | 101 | 25 |
| Metformin Hcl | Metformin Hcl | 96 | 24 |
| Gabapentin | Gabapentin | 89 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 16 |
| Simvastatin | Simvastatin | 79 | 24 |
| Bupropion Xl | Bupropion Hcl | 71 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 16 |
| Trazodone Hcl | Trazodone Hcl | 59 | 24 |
| Eliquis | Apixaban | 56 | suppressed |
| Allopurinol | Allopurinol | 54 | 15 |
| Metformin Hcl Er | Metformin Hcl | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 20 |
| Donepezil Hcl | Donepezil Hcl | 47 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Furosemide | Furosemide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 15 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Diovan | Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.42 · 18 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BYETTA, Belbuca, CAPVAXIVE, COMIRNATY, EVENITY, GARDASIL 9, LEQVIO, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error